- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.07. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes $1.36-million financing | 1 | Stockwatch | ||
| SHARP THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 29.07. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Non-Brokered Private Placement | 413 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has... ► Artikel lesen | |
| 21.07. | Sharp Therapeutics Corp.: Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders | 466 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing... ► Artikel lesen | |
| 16.07. | Sharp Therapeutics Corp (2): Sharp Therapeutics arranges $1.36M private placement | 2 | Stockwatch | ||
| 15.07. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Non-Brokered Private Placement and Provides Operational Update | 315 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it is... ► Artikel lesen | |
| 30.06. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date | 534 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that its annual meeting... ► Artikel lesen | |
| 09.06. | Sharp Therapeutics Corp (2): Sharp Therapeutics debenture private placement | 1 | Stockwatch | ||
| 28.05. | Sharp Therapeutics Presents New Preclinical Data Supporting Novel Small-Molecule Therapeutic Approach for Niemann-Pick Disease Type C | 3 | GlobeNewswire (USA) | ||
| 18.04. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes $1.55M (U.S.) note financing | 1 | Stockwatch | ||
| 18.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Corp. Announces Fourth Quarter 2025 Results, Closing of Convertible Note Offering and Adoption of Semi-Annual Reporting | 910 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 17, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its annual... ► Artikel lesen | |
| 11.04. | Sharp Therapeutics Corp (2): Sharp seeks replacement compound for Gaucher, GBA1 | 1 | Stockwatch | ||
| 11.04. | Sharp Therapeutics Corp (2): Sharp closes $200k (U.S.) fourth tranche of placement | 3 | Stockwatch | ||
| 10.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs | 1.022 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that following longer-term... ► Artikel lesen | |
| 10.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Fourth Tranche of Unsecured Convertible Note Offering | 1.070 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it... ► Artikel lesen | |
| 03.04. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes third tranche of offering | 1 | Stockwatch | ||
| 02.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering | 1.006 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has... ► Artikel lesen | |
| 13.03. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering | 908 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it... ► Artikel lesen | |
| 27.02. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering | 678 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that... ► Artikel lesen | |
| 02.02. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes | 384 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce the terms... ► Artikel lesen | |
| 19.12.25 | Sharp Therapeutics Corp.: Sharp Therapeutics Provides Update on Non-Brokered Private Placement and Grant of Options | 655 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - December 19, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DYNE THERAPEUTICS | 16,030 | 0,00 % | Aktien New York: Dow mit schwachem Wochenauftakt - Nasdaq im Plus | NEW YORK (dpa-AFX) - An der Wall Street hat der Handel am Dienstag nach dem verlängerten Wochenende schwach begonnen. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst vor bald... ► Artikel lesen | |
| DISC MEDICINE | 65,24 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,320 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 280,81 | 0,00 % | H.C. Wainwright reiterates Praxis Precision stock rating on pipeline potential | ||
| TANGO THERAPEUTICS | 24,910 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 39,340 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,920 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 35,930 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 14,470 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME | 4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,615 | 0,00 % | Citizens reiterates Summit Therapeutics stock rating on trial data | ||
| CULLINAN THERAPEUTICS | 14,810 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio | Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren's disease in December CLN-049 (FLT3 TCE)... ► Artikel lesen | |
| IMMUNOME | 21,415 | 0,00 % | Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027 | ||
| CLIMB BIO | 11,660 | 0,00 % | Climb Bio, Inc.: Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy | ~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse... ► Artikel lesen | |
| PARABILIS MEDICINES | 31,200 | 0,00 % | Parabilis Medicines, Inc.: Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates | Advanced zolucatetide across multiple Wnt/ß-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with... ► Artikel lesen | |
| RELAY THERAPEUTICS | 17,470 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen |
Das Unternehmen SHARP THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHARP THERAPEUTICS CORP finden Sie auf Wallstreet Online.